Alto Neuroscience reports positive outcomes from Phase IIb trial of MDD therapy
Alto Neuroscience has reported positive outcomes from the interim analysis of its double-blind Phase IIb trial of oral ALTO-300, as…
Alto Neuroscience has reported positive outcomes from the interim analysis of its double-blind Phase IIb trial of oral ALTO-300, as…
Annovis Bio has commenced the treatment of first two subjects in a randomised Phase III clinical trial to assess the…
Mind Medicine (MindMed) has dosed the first subject in the Phase III Panorama study of a proprietary form of lysergide…
Imvax has received $29m in a financing round from current investors, aimed at advancing the Phase IIb trial of its…
The US Food and Drug Administration (FDA) has lifted a clinical hold on Amylyx Pharmaceuticals’ Phase I trial of AMX0114…
HMNC Brain Health (HMNC) has completed the subject randomisation in its placebo-controlled Phase IIb OLIVE trial of a vasopressin V1b…
The Alzheimer’s disease market is expected to grow at a high compound annual growth rate (CAGR) of 23.4% from $2.4bn…
Contineum Therapeutics has concluded the targeted enrolment of 168 subjects in its Phase II trial of M1 receptor antagonist PIPE-307…
BIAL has reported the completion of the full dose regimen for the first subject in the multicentre Phase II ACTIVATE…
Israeli Medical Cannabis Agency (IMCA) at the Ministry of Health has renewed SciSparc’s clinical trial of SCI-210 aimed at treating…